A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Safinamide (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Newron Sweden AB
  • Most Recent Events

    • 14 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 14 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top